{"id":"rosuvastatin-active-capsule","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-7","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"2-4","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, blocking the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This leads to decreased intracellular cholesterol production, upregulation of LDL receptors on hepatocytes, and increased clearance of LDL cholesterol from the bloodstream. The net result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:30.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary prevention of cardiovascular disease"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT05850091","phase":"PHASE4","title":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-07","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT02741245","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-06-09","conditions":"Hypercholesterolemia","enrollment":321},{"nctId":"NCT04931147","phase":"PHASE1","title":"A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-05-13","conditions":"Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis","enrollment":90},{"nctId":"NCT01218802","phase":"PHASE2","title":"Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-02","conditions":"HIV Infections, Heart Disease","enrollment":147},{"nctId":"NCT01798602","phase":"PHASE2","title":"Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial","status":"TERMINATED","sponsor":"Canadian Critical Care Trials Group","startDate":"2009-12","conditions":"H1N1 Influenza","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rosuvastatin active capsule","genericName":"Rosuvastatin active capsule","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}